AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
It seems like your message might be incomplete or empty. Could you please provide more details or clarify what you're asking for? I'm here to help with any questions or tasks you have! .
ByAinvest
Monday, Nov 10, 2025 10:27 am ET1min read
InflaRx surged 35.37% intraday trading, driven by positive Phase 2a clinical data for INF904 in hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU). The trial showed 29/31 HS patients and 30/31 CSU patients experienced rapid reduction in abscesses/nodules with no safety signals, including a 13.7-point average decrease in UAS7 scores for CSU patients (15.4 points in severe cases) and no serious adverse reactions.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet